Deferred Revenues - Additional Information (Detail) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011	Nov. 30, 2002
Deferred Revenue Arrangement [Line Items]
Sales price for undivided interest in the Company's rights to future Abreva royalties				$ 24,100,000
Expiration of the patent for Abreva	Apr. 30, 2014
Annual net sales of Abreva	62,000,000	62,000,000	62,000,000
Revenues from royalties	4,453,707	4,200,506	4,406,589
GSK License Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Right to receive royalties	50.00%
Right to receive royalties, net	4.00%
Revenues from royalties	$ 1,700,000	$ 1,600,000	$ 1,500,000